Form 4 for WVE Wave Life Sciences, Inc.
Accepted 2024-04-05 00:00:00 ET · period of report 2024-04-03 · accession 0000950170-24-042381 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2024-04-05 | 2024-04-03 | WVE | Moran Kyle | CFO | S - Sale | $6.17 | -15.6K | 33.9K | -32% | -$96.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2024-04-03 | S | D | 15,630 | $6.17 | 33,921 | D | — | — | (F2) The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $6.115 to $6.23 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. (F3) Includes 3,431 ordinary shares acquired on January 14, 2024, under the issuer's 2019 Employee Share Purchase Plan. |